1. Pharmacokinetics of the novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat;Albayati;Drug Metab. Dispos.,2008
2. Craving, withdrawal, and smoking urges on days immediately prior to smoking relapse;Allen;Nicotine Tob. Res.,2008
3. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1;Amos;Nat. Genet.,2008
4. Mechanisms of action of adjuvants;Awate;Front. Immunol.,2013
5. Beckmann, J.S., Meyer, A.C., Pivavarchyk, M., Horton, D.B., Zheng, G., Smith, A.M., McIntosh, M., Crooks, P.A., Bardo, M.T., Dwoskin, L.P., r-bPiDI acts selec- tively at α6β2* nicotinic receptors to decrease nicotine-evoked dopamine release and nicotine reinforcement. Neuropharmacology (under review).